GlassScriptPhysician profile
Thomas Migliaccio
NPI 1487860359
$4,054.21
in general payments reported to CMS, 2019-2025
32 companies · $338 in 2025
The $338 reported for 2025 was more than what a typical provider received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,149 · 2020: $191 · 2021: $1,226 · 2022: $627 · 2023: $217 · 2024: $307 · 2025: $338.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $862.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $861.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celularity INC. | $2,112.00 | 2019-2022 | |
| Astellas Pharma US INC | $253.44 | 2023-2025 | Veozah |
| Abbvie INC. | $252.12 | 2019-2023 | |
| Hologic Sales and Service, LLC | $215.07 | 2021-2024 | Myosure Tissue Removal Device |
| Gynesonics, INC. | $111.63 | 2021 | |
| Mayne Pharma Commercial LLC | $99.56 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $76.45 | 2020-2025 | |
| Allergan, INC. | $73.54 | 2019-2020 | |
| Exeltis, USA INC. | $73.05 | 2024-2025 | Slynd |
| Merck Sharp & Dohme LLC | $65.22 | 2019-2024 | Gardasil, Gardasil 9 |
| Exact Sciences Corporation | $60.59 | 2023-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Coopersurgical, INC. | $50.74 | 2019-2020 | |
| Pfizer INC. | $49.65 | 2021-2024 | |
| Davol INC. | $48.01 | 2025 | Channel Drain |
| Therapeuticsmd, INC. | $44.89 | 2019-2021 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $44.50 | 2024 | Channel Drain |
| Minerva Surgical, INC | $41.76 | 2019-2024 | |
| Evofem Biosciences, INC. | $40.75 | 2022-2023 | Phexxi |
| Scynexis, INC. | $39.97 | 2022 | |
| Organon LLC | $34.02 | 2024-2025 | Nexplanon |
| Cumberland Pharmaceuticals, INC. | $31.70 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $28.79 | 2019-2024 | Trintellix |
| Dysis Medical, INC. | $27.45 | 2020-2021 | |
| Avanos Medical | $27.13 | 2019 | |
| Lupin INC. | $26.65 | 2019-2020 | |
| Avion Pharmaceuticals | $25.74 | 2022 | |
| Myovant Sciences INC. | $25.13 | 2021-2022 | |
| Daiichi Sankyo INC. | $17.00 | 2023 | Injectafer |
| Amag Pharmaceuticals, INC. | $15.00 | 2021 | |
| Agile Therapeutics, INC. | $14.29 | 2022 | |
| Duchesnay USA Incorporated | $14.20 | 2019 | |
| Sumitomo Pharma America, INC. | $14.17 | 2023 | Myfembree |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Migliaccio listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.